Jarius, S.
Würthwein, C.
Behrens, J. R.
Wanner, J.
Haas, J.
Paul, F.
Wildemann, B.
Funding for this research was provided by:
Dietmar Hopp Foundation
Merck Serono
German Federal Ministry of Education and Research
German Federal Ministry of Education and Research
Deutsche Forschungsgemeinschaft
Article History
Received: 15 November 2017
Accepted: 14 December 2017
First Online: 18 January 2018
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: B.W. has received research grants, speaking fees and travel grants from Merck Serono, Biogen, Teva, Novartis, Sanofi Genzyme, Bayer Healthcare, Biotest and the Dietmar Hopp Foundation. F.P. has received research support from Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis/Genzyme, Merck Serono, Alexion, Chugai, Arthur Arnstein Foundation Berlin, Guthy Jackson Charitable Foundation and the US National Multiple Sclerosis Society; has received travel funding and/or speaker honoraria from Bayer, Novartis, Biogen Idec, Teva, SanofiAventis/Genzyme and Merck Serono; and has consulted for Sanofi Genzyme, Biogen Idec and MedImmune; none of this is related to the present paper. The other authors report no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.